| Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six … D Arnold, B Lueza, JY Douillard, M Peeters, HJ Lenz, A Venook, ... Annals of Oncology, 0 | 871 | |
| Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis D De Ruysscher, B Lueza, C Le Péchoux, DH Johnson, M O'brien, ... Annals of Oncology 27 (10), 1818-1828, 2016 | 109 | 2016 |
| Extrapolation of survival curves from cancer trials using external information P Guyot, AE Ades, M Beasley, B Lueza, JP Pignon, NJ Welton Medical Decision Making 37 (4), 353-366, 2017 | 79 | 2017 |
| Surrogate end points for overall survival in loco-regionally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis F Rotolo, JP Pignon, J Bourhis, S Marguet, J Leclercq, W Tong Ng, J Ma, ... JNCI: Journal of the National Cancer Institute 109 (4), 2017 | 46 | 2017 |
| Erratum to: Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis B Lueza, F Rotolo, J Bonastre, JP Pignon, S Michiels BMC medical research methodology 16 (1), 71, 2016 | 44* | 2016 |
| Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis B Lueza, F Rotolo, J Bonastre, JP Pignon, S Michiels BMC medical research methodology 16 (1), 37, 2016 | 44 | 2016 |
| Circulating innate immune markers and outcomes in treatment-naïve advanced non–small cell lung cancer patients M Charrier, L Mezquita, B Lueza, L Dupraz, D Planchard, J Remon, ... European Journal of Cancer 108, 88-96, 2019 | 37 | 2019 |
| Cost effectiveness of molecular profiling for adjuvant decision making in patients with node-negative breast cancer J Bonastre, S Marguet, B Lueza, S Michiels, S Delaloge, M Saghatchian Journal of Clinical Oncology 32 (31), 3513-3519, 2014 | 28 | 2014 |
| Cost Effectiveness of Modified Fractionation Radiotherapy versus Conventional Radiotherapy for Unresected Non–Small-Cell Lung Cancer Patients BLT Ramaekers, MA Joore, B Lueza, J Bonastre, A Mauguen, JP Pignon, ... Journal of Thoracic Oncology 8 (10), 1295-1307, 2013 | 28 | 2013 |
| LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non–small-cell Lung Cancer L Seymour, G Le Teuff, E Brambilla, FA Shepherd, JC Soria, R Kratzke, ... Clinical lung cancer 20 (2), 66-73. e6, 2019 | 26 | 2019 |
| How to Model Survival In Cost-Effectiveness Analysis? Differences Between Markov and Partitioned Survival Analysis Models R Minacori, J Bonastre, B Lueza, S Marguet, P Levy Value in Health 18 (7), A704, 2015 | 22 | 2015 |
| Difference in Restricted Mean Survival Time for Cost-Effectiveness Analysis Using Individual Patient Data Meta-Analysis: Evidence from a Case Study B Lueza, A Mauguen, JP Pignon, O Rivero-Arias, B Julia PLoS ONE 11 (3), 2016 | 20 | 2016 |
| Individual patient data network meta-analysis using either restricted mean survival time difference or hazard ratios: is there a difference? A case study on locoregionally … C Petit, P Blanchard, JP Pignon, B Lueza Systematic reviews 8, 1-12, 2019 | 13 | 2019 |
| ALK amplification and crizotinib sensitivity in non-small cell lung cancer cell lines and patients report. K Khadija, N Auger, B Lueza, F Commo, A Valent, V Rousseau, ... JOURNAL OF CLINICAL ONCOLOGY 30 (15), 2012 | 9 | 2012 |
| Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients L Mezquita, M Charrier, L Faivre, L Dupraz, B Lueza, J Remon, ... Lung Cancer 112, 10-15, 2017 | 5 | 2017 |
| Phase III trial of concurrent thoracic radiotherapy with either first-or third-cycle chemotherapy for limited-disease small-cell lung cancer B Lueza, C Le Péchoux, JP Pignon Annals of Oncology 25 (9), 1865-1866, 2014 | 3* | 2014 |
| Cost-effectiveness of transcatheter aortic valve implantation in patients at low surgical risk in France: a model-based analysis of the Evolut LR trial D Tchétché, CD de Gennes, Q Cormerais, BP Geisler, C Dutot, ... The European Journal of Health Economics, 1-11, 2023 | 1 | 2023 |
| POSB49 Cost Effectiveness Model of Atezolizumab Plus Bevacizumab in Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) in French Setting CD de Gennes, B Mazaleyrat, JS Alvarez, B Lueza Value in Health 25 (1), S69, 2022 | 1 | 2022 |
| PCN205 COMPARISON OF METHODS TO ACCOUNT FOR CURED PATIENTS IN A COST-EFFECTIVENESS ANALYSIS: A CASE STUDY IN ONCOLOGY AF Colonier, V Genestier, B Lueza Value in Health 22, S475, 2019 | 1 | 2019 |
| Abstract B45: Upfront genomic testing in non-small cell lung cancer (NSCLC) patients: Preliminary result of the MSN study D Planchard, L Lacroix, T Le Chevalier, JC Soria, B Besse, A Celebic, ... Clinical Cancer Research 18 (3_Supplement), B45-B45, 2012 | 1 | 2012 |
Stefan MichielsOffice Biostatistics & Epidemiology, Gustave Roussy; Oncostat, Univ. Paris Saclay, INSERMVerified email at gustaveroussy.fr
